Asmalin MDI

Relief of bronchospasm associated w/ reversible obstructive airway diseases eg, bronchial asthma & COPD. Prevention of exercise-induced bronchospasm if the drug is to be given before exertion.

Relief of bronchospasm Adult & childn ≥4 yr 1 or 2 inhalations every 4-6 hr as needed. Prevention of exercise-induced bronchospasm Adult 2 inhalations 15-30 min before exercise. Childn ≥4 yr 1 or 2 inhalations 15-30 min before exercise.

Hypersensitivity. Tocolytic therapy (eg, eclampsia or severe preeclampsia, intrauterine infection/fetal death, antepartum hemorrhage, placenta previa, cord compression, or toxemia of pregnancy). Not to be used for threatened abortion.

Discontinue use if paradoxical bronchospasm occurs. Consider possible need for anti-inflammatory treatment (eg, corticosteroids) if deterioration of asthma occurs; monitor daily peak flow in patients at risk. Caution in patients w/ acute severe asthma where concomitant therapy w/ corticosteroids, xanthine derivatives, or diuretics, & by hypoxia may result in hypokalemia; coexisting conditions eg, CV disorders including coronary insufficiency, cardiac arrhythmias, or HTN; convulsive disorders; hyperthyroidism & thyrotoxicosis; DM; patients who are unusually responsive to sympathomimetic amines. Monitor K conc in severe asthma. May induce reversible metabolic changes (eg, increased blood sugar levels). Use in pregnancy, labor, & lactation only if the potential benefit justifies the potential risk. Safety & efficacy have not been established in childn <4 yr. Use w/ caution & start at the lower end of the usual dosing range due to frequency of decreased hepatic, renal, &/or cardiac function & of concomitant disease & drug therapy in elderly ≥65 yr.

UTI; hypersensitivity; DM, edema, hypokalemia, metabolic acidosis; aggressive behavior, anxiety, depression, dysphonia/voice alteration, hyperactivity, insomnia, nervousness, nightmare, somnolence; agitation, altered taste, central nervous stimulation, dizziness, headache, hyperkinesia, inhalation site/taste sensation, lightheadedness, tremor, vertigo; ear disorder, ear pain, tinnitus; angina, cardiac arrhythmias, dyspnea, myocardial ischemia, palpitations, tachycardia; epistaxis, HTN, peripheral vasodilatation; asthma exacerbation, cough, flu syndrome, paradoxical bronchospasm, pharyngitis, rhinitis, URTI; altered taste, constipation, diarrhea, discoloration of teeth, dry mouth, eructation, flatulence, gagging, gastroenteritis, glossitis, heartburn, mouth & throat irritation, nausea, stomachache, tongue ulceration, vomiting; back pain, muscle cramps; ataxia, fever, increased sweating; accidental injury.

Serious adverse CV effects w/ sympathomimetic agents or epinephrine. Inhibited effect w/ β-adrenergic blocking agents (eg, propranolol). Concurrent administration w/ corticosteroids may exacerbate the decrease in K conc or enhance hyperglycemic effects; monitor K & blood sugar levels. ECG changes &/or hypokalemia w/ non-K-sparing diuretics (eg, loop or thiazide diuretics). Decreased serum digoxin conc. Potentiated effect on the vascular system w/ MAOIs (eg, rasagiline) or TCAs (eg, clomipramine). Enhanced hypokalemic effect w/ xanthines eg, theophylline.

Antiasthmatic & COPD Preparations

R03AC02 - salbutamol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.

Rx